Form 4: Boston Scientific CEO Michael Mahoney Reports Share Transactions
SEC Form 4 Filing
Michael Mahoney, Chairman, President & CEO of Boston Scientific, reports acquisition and disposal of common stock on February 11, 2025, according to a Form 4 filing.
Summary
- Michael F. Mahoney, the Chairman, President & CEO of Boston Scientific Corp (BSX), filed a Form 4 detailing changes in beneficial ownership.
- On February 11, 2025, Mahoney acquired 130,118 shares of common stock at $0.00, and disposed of 62,915 shares at $105.98.
- Following these transactions, Mahoney directly owns 1,619,873 shares and indirectly owns 201,478 shares through a trust.
- The acquisition of 130,118 shares was related to performance share units awarded on February 16, 2022, under the 2022 Total Shareholder Return Performance Share Program, which vested after a three-year performance cycle ending December 31, 2024, and satisfaction of the individual service period.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing of stock transactions by an executive. The vesting of performance share units suggests the company met certain performance goals, which is mildly positive.
Positives
- The vesting of performance share units indicates that Boston Scientific met certain performance criteria related to shareholder return.
Industry Context
Form 4 filings are standard practice for corporate insiders to report transactions in their company's stock, providing transparency to investors.
Comparison to Industry Standards
- Executive compensation packages often include performance-based equity awards, such as the performance share units granted to Michael Mahoney, to align management's interests with those of shareholders.
- The vesting of these units based on total shareholder return relative to the S&P 500 Health Care Index is a common metric used in the healthcare industry to incentivize performance.
- Similar companies like Medtronic (MDT) and Abbott Laboratories (ABT) also utilize performance-based equity compensation for their executives.
Stakeholder Impact
- The vesting of performance share units and subsequent stock transactions may have a minor impact on shareholders by increasing the number of shares outstanding.
Key Dates
| Date | Description |
|---|---|
| 02/16/2022 | Reporting person was awarded a target number of performance share units under the Company's 2022 Total Shareholder Return Performance Share Program |
| 12/31/2024 | End of the three-year performance cycle for the performance share units. |
| 02/11/2025 | Date of stock acquisition and disposal transactions. |
| 02/13/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.